fluid, and immune cells across vessels into tissues. Therefore, maintenance of vascular endothelial integrity is crucial for vascular and tissue homeostasis. However, the underlying mechanisms mediating endothelial activation in response to lipopolysaccharide remain largely unknown.
TLR4 (toll-like receptor 4) has been recognized as the major receptor for lipopolysaccharide. Ligation of lipopolysaccharide to TLR4 activates nuclear factor (NF) κB and nuclear factor of activated T cells (NFAT) pathways. In human umbilical vein endothelial cells, TLR4, MyD88 (myeloid differentiation primary response gene 88), and Mal/TIRAP (MyD88 adapter-like/toll/interleukin-1 receptor domain-containing adapter protein) adaptor proteins are required for the activation of NFκB and production of interleukin-6 (IL-6). 5 Animal studies with inactive NFκB signaling indicate that, in response to lipopolysaccharide-induced endotoxemia, NFκB activation acts as a quick adaptive response, which provides important survival signal and maintains a normal but dynamic endothelial barrier function. 6 However, lipopolysaccharide activates transcriptional factor NFAT in endothelial cells, which results in increased expression of proinflammatory cytokines, such as interferon-γ and TNFα (tumor necrosis factor-α). 7 The activation of NFAT is mediated by reactive oxygen species-driven Ca 2+ signaling pathway, and TLR4 may be required for reactive oxygen species generation. 7 In activated immune cells, such as dendritic cells, CD14 is another receptor of lipopolysaccharide for NFAT activation, likely through Src-family kinase and phospholipase Cγ2 and Ca 2+ /calcineurin signaling. 8 In endothelial cells, CD14 has also been suggested to function together with TLR4 for lipopolysaccharide-induced E-selectin and IL-6 production. 9 Although the exact roles of TLR4 and CD14 in lipopolysaccharide-mediated NFAT activation and endothelial inflammatory responses remain to be further clarified, NFAT activation is recognized as a crucial transcription factor controlling the expression of proinflammatory cytokines. 7 Endothelial integrity and vascular homeostasis are tightly regulated by multiple signaling pathways, such as BMP (bone morphogenetic protein) signaling. 10 BMPER (BMPbinding endothelial regulator), an extracellular regulator of BMPs, 11, 12 has been identified as an important regulator of vascular inflammation and atherosclerosis. [13] [14] [15] Knockdown of BMPER by its specific small interfering RNA (siRNA) or its deficiency in BMPER +/− mice potentiates TNFα-induced endothelial inflammatory responses.
14 This anti-inflammatory phenotype of BMPER is mediated by blocking BMP activity, which likely explains the atheroprotective function of BMPER. 15 However, it is not clear whether BMPER regulates inflammatory responses in endothelial cells in an acute setting, such as lipopolysaccharide challenge. We have recently demonstrated that LRP 1 (low-density lipoprotein receptor-related protein 1), a member of the low-density lipoprotein receptor family, is associated with BMPER and regulates angiogenesis during zebrafish vein development. 16 The mature form of LRP1 is a heterodimer composed of a 515-kDa α chain (LRP1α), possessing 4 extracellular ligand binding domains, and an 85-kDa membrane-anchored cytoplasmic β chain (LRP1β), which remains noncovalently associated with α chain. LRP1 is an endocytic receptor for multiple signaling pathways and mediates their signals through its β chain, which interacts with many scaffolding proteins. [17] [18] [19] [20] [21] [22] [23] In addition, processed forms of LRP1β can also translocate into nucleus and regulate the enzyme activity of poly(ADP-ribose) polymerase-1 24 and expression of PPAR (peroxisome proliferator-activated receptor) target genes by acting as a PPARγ coactivator. 25 Although LRP1 is required for the endocytosis of BMPER signaling complex in endothelial cells, it remains elusive whether the coupling of BMPER to LRP1 may also initiate their own signaling events.
BMPER null mice die at birth. 11 In this study, we used mice with BMPER haploinsufficiency to study the effect of reduced BMPER expression on lipopolysaccharide-induced endothelial inflammation. Surprisingly, we observed that BMPER +/− mice exhibit reduced vascular inflammatory responses on lipopolysaccharide treatment as shown by several parameters, including wet/dry lung weight ratio, pulmonary edema, survival rate, and production of proinflammatory cytokines. Interestingly, BMPER activates NFATc1 in a LRP1-dependent but BMP-independent manner. Furthermore, the co-ordinative actions of LRP1/NF45 (nuclear factor 45) nuclear export and NFATc1 nuclear import may play a crucial role for BMPER-induced NFATc1 activation. These results indicate that inhibition of BMPER signaling limits endotoxemia-induced pulmonary inflammatory responses and that BMPER/LRP1 signaling axis may provide potential therapeutic targets against sepsis-induced acute lung injury.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

BMPER Haploinsufficiency Ameliorates Pulmonary Vascular Leakage and Lung Injury in Response to Lipopolysaccharide Treatment
Accumulated evidence suggests that BMPER protects endothelial cells from chronic inflammation and atherosclerosis by inhibiting BMP activity. [13] [14] [15] Figure 1A and 1B) . Similarly, the lung wet/ dry weight ratio of BMPER +/− mice, after lipopolysaccharide injection, was significantly smaller than that of BMPER +/+ mice ( Figure 1C ). In addition, when challenged with a lethal dose of lipopolysaccharide (15 mg/kg), all BMPER +/+ mice died within 2 days while the majority of BMPER +/− mice recovered from this challenge with a 7-day survival rate at ≈62.5% ( Figure 1D ). Then we evaluated histopathologic changes of lung in mice after lipopolysaccharide-induced acute lung injury. Consistently, we observed a marked increase of inflammatory cell infiltration, interalveolar septal thickening, and interstitial edema in BMPER +/+ mice after lipopolysaccharide challenge ( Figure 1E ). However, BMPER +/− mice showed alleviated phenotypes of lung injury and a much reduced lung injury score ( Figure 1E and 1F) . These data suggest that BMPER haploinsufficiency protects lung from endotoxemiainduced injury. (Figure 2A-2C ; data not shown). To further access the influence of BMPER haploinsufficiency on pulmonary inflammation, we determined in bronchoalveolar lavage fluid (BALF) several parameters of lung inflammation, including cell infiltration, myeloperoxidase activity, protein content, and the levels of interferon γ, IL-6, and TNF-α. In response to lipopolysaccharide, both BMPER +/+ and BMPER +/− mice exhibited increased leukocyte infiltration into BALF, assessed by measuring the total recovered cell numbers of BALF. However, cell counts in BALF of BMPER +/− mice were significantly lower than those in BMPER +/+ mice ( Figure 2D ). In addition, myeloperoxidase activity was also dramatically lower in BMPER +/− mice compared with BMPER +/+ mice ( Figure 2E ). These results suggest that BMPER haploinsufficiency blocks leukocyte infiltration into alveolar space. Next, we measured total protein and cytokine levels in BALF and found that the protein level and individual levels of interferon γ, IL-6, and TNF-α were significantly decreased in BMPER +/− mice ( Figure 2F-2I ). Taken together, BMPER
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+/− mice demonstrate alleviated pulmonary inflammatory response on lipopolysaccharide challenge, exhibiting reductions in leukocyte infiltration and proinflammatory cytokine production.
Reports show that pulmonary microvascular endothelial cell apoptosis also contributes to pulmonary microvascular barrier dysfunction and edema during sepsis. 26 Therefore, we tested whether BMPER deficiency results in endothelial cell apoptosis in response to lipopolysaccharide. As expected, lipopolysaccharide injection in BMPER +/+ mice induced vascular cell apoptosis as measured by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) analysis ( Figure IIA and IIB in the online-only Data Supplement). However, TUNEL-positive cell number significantly decreased in BMPER +/− mice. This protective effect of BMPER haploinsufficiency was also observed in primary mouse lung microvascular endothelial cells (MLECs; Figure IIC and IID in the online-only Data Supplement). We also assessed the effects of BMPER haploinsufficiency on endothelial permeability, and we measured solute flux of fluorescein isothiocyanate-dextran across the endothelial monolayer. Lipopolysaccharide treatment led to a 2.2-fold increase in paracellular permeability ( Figure IIE in the online-only Data Supplement). However, this lipopolysaccharide-mediated permeability was partially inhibited in BMPER knockdown MLECs. Surprisingly, the protein level of claudin 5, a key determinant of endothelial permeability, was not affected by BMPER treatment ( Figure IIF in the online-only Data Supplement), suggesting that BMPER-dependent permeability change is likely mediated through other mechanisms. Taken all together, these data suggest that BMPER deficiency reduces endothelial cell apoptosis and permeability in response to lipopolysaccharide.
BMPER Is Required for LipopolysaccharideInduced NFATc1 Activation in Endothelial Cells
Host inflammatory response, rather than the nature of pathogen, is the primary determinant for the outcome of sepsis patients. 3 Endothelial cell is one of the major cornerstones of the innate immune responses by initiating a cascade of signaling responses to defend the pathogen. 3 Our group and other laboratories have demonstrated that BMPER is a key regulator of endothelial cell function. [12] [13] [14] [15] [16] [27] [28] [29] [30] In particular, BMPER can be induced by inflammatory-regulatory stimuli, such as oscillatory shear stress and mevastatin, and inhibits endothelial inflammatory responses. 13, 15 BMPER haploinsufficiency inhibition of lipopolysaccharide-induced lung injury was unexpected because of the known anti-inflammatory role of BMPER in chronic inflammatory responses. Therefore, these data suggested that BMPER might regulate acute and chronic inflammatory responses through distinctive pathways. We tested whether BMPER plays a role in lipopolysaccharide signaling pathway in endothelial cells. By using MLECs, we investigated whether NFAT, an important transcription factor of lipopolysaccharide-induced acute inflammatory responses in endothelial cells, 7 can be regulated by BMPER. As expected, lipopolysaccharide increased NFAT activity as measured by NFAT reporter luciferase activity ( Figure 3A) . However, when BMPER expression in MLECs was knocked down with its specific siRNA ( Figure IIIA in the online-only Data Supplement), we observed an ≈2-fold decrease in NFAT activation compared with control MLECs ( Figure 3A ). These data suggest that BMPER is required for NFAT activation in response to lipopolysaccharide.
BMPER Activates NFATc1 Signaling
To understand the underlying molecular mechanisms responsible for BMPER's action, we performed gene profiling analysis with BMPER-treated endothelial cells and searched for changes in gene expression. Microarray analysis of endothelial cells treated with BMPER or control revealed that BMPER elicits either upregulation or downregulation of genes that are not associated with BMP transcriptional regulation ( Figure  IIIB in the online-only Data Supplement). To further examine these observations, we used TRANSFAC analysis to map transcription factor binding sites upstream of the identified BMP-independent BMPER-regulated genes. Interestingly, we found that several genes regulated by BMPER contain NFAT consensus binding sites, including phospholipase Cβ1 and NFATc1, which itself is a member of NFAT transcription factors. There are mainly 5 members of NFAT transcriptional factors that are evolutionarily related to the REL-NF-κB family of transcription factors: NFAT1 (also known as NFATc2 or NFATp), NFAT2 (also known as NFATc1 or NFATc), NFAT3 (also known as NFATc4), NFAT4 (also known as NFATc3 or NFATx), and NFAT5 (also known as tonicity enhancer binding protein). To examine the relationship between BMPER and NFAT, we assessed the induction of NFATs in response to BMPER treatment. By performing real-time polymerase chain reaction analysis, we demonstrated that NFATc1 was the most induced NFAT in response to BMPER treatment, with the peak at 1 hour ( Figure IIIC in the online-only Data Supplement). Next, we tested whether BMPER could activate NFAT by performing the NFAT reporter assay in endothelial cells in response to BMPER. When mouse lung endothelial cells were treated with BMPER, we observed an increase in NFAT transcriptional activity ( Figure 3B ). Because NFATc1 needs to be dephosphorylated and then translocated from cytoplasm to the nucleus for fully activation, we performed fractionation assays to determine whether subcellular localization of NFATc1 can be regulated by BMPER. We observed an increase of NFATc1 accumulation in the nucleus after BMPER treatment for 15 to 60 minutes ( Figure 3C and 3D) . Immunostaining also confirmed the nuclear translocation of NFATc1 in response to BMPER in endothelial cells ( Figure IIID in the online-only Data Supplement). A large number of NFAT target genes, including interferon γ, are reported. 31, 32 Given that interferon γ levels in BALF and serum were decreased in BMPER +/− mice (Figure 2A and 2G), we tested whether NFATc1 is required for interferon γ induction in MLECs. Importantly, BMPER treatment dramatically increased the mRNA level of interferon γ in MLECs ( Figure 3E ). However, knockdown of NFATc1 by its specific siRNA significantly blocked the induction of interferon γ ( Figure 3E ). Using chromatin immunoprecipitation assays, we discovered that the association of NFATc1 with the promoter of interferon γ was increased in response to BMPER treatment ( Figure IIIE in the online-only Data Supplement). Taken together, these data suggest that BMPER is not only necessary but also sufficient for NFATc1 activation and the induction of its target gene interferon γ in endothelial cells.
LRP1 Mediates NFAT Activation Induced by BMPER
To determine how BMPER activates NFATc1, inhibitors of different signaling pathways were used to dissect downstream signaling pathways. Importantly, we showed that cyclosporin A (calcineurin inhibitor) and U0126 (MEK1 [mitogen-activiated protein kinase kinase 1]/ERK [extracellular signal-regulated kinase] inhibitor) blocked the activation of NFAT on BMPER treatment ( Figure 4A ). In addition, the inhibition of calcineurin activity by cyclosporin A improved the survival rate of BMPER +/+ mice on lipopolysaccharide challenge at 15 mg/kg ( Figure IVA in the online-only Data Supplement), which phenocopies the protective effect of BMPER haploinsufficiency ( Figure 1D ). However, Smad6, which is the inhibitor of the BMP's downstream signaling mediators Smad1, 5, and 8, failed to inhibit NFAT activation ( Figure 4A ), suggesting that BMPER activates NFAT through BMP-independent pathways. We have recently demonstrated that LRP1 is associated with BMPER and is required for BMPER's regulatory effects on angiogenesis. 16 Given that the intracellular domain of LRP1β contains multiple serine, threonine, and . BMPER (bone morphogenetic protein-binding endothelial regulator) is required and sufficient to activate nuclear factor of activated T cell (NFAT) c1. A, BMPER knockdown blocks NFAT activation in response to lipopolysaccharide (LPS; 0 μg/mL). Mouse lung microvascular endothelial cells (MLECs) were transfected with a mixture of NFAT-responsive firefly luciferase and renilla constructs, and BMPER or control small interfering RNA (siRNA). One day later, cells were treated with LPS, and the luciferase activity was measured after another day's incubation. B, BMPER increases transcriptional activity of NFAT in MLECs. MLECs were transfected with a mixture of NFATresponsive firefly luciferase and renilla constructs. After 24 h, cells were treated with BMPER or control for another 24 h, and the luciferase activity was measured. C and D, BMPER increases nuclear translocation of NFATc1. MLECs were treated with 10 nmol/L BMPER for indicated time periods. Nuclear and cytoplasmic-enriched fractions of cell lysates were used to determine the translocation of NFATc1. Lamin B1 (nuclear marker) and HSP90 (cytosol marker) immunoblotting were used to verify the purity of the fractions. NFATc1 protein levels in nuclear and cytosol fractions were quantified and shown in (D). E, NFATc1 is required for interferon (IFN) γ induction on BMPER treatment. MLECs were transfected with NFATc1 or control siRNA. After 24 h, cells were treated with BMPER at 10 nmol/L or control and incubated for another 8 h. Cells were harvested for real-time polymerase chain reaction with IFN γ-specific probe and primers. *P<0.05, compared with cells without LPS (A) or BMPER (B, D, E) treatment; #P<0.05; n=3 to 6. Analysis was 2-way ANOVA followed by Fisher least significant difference multiple comparison test (for A and E) and 1-way ANOVA (for B and D).
tyrosine residues that can be phosphorylated by PKA (cAMPdependent protein kinase A-inhibitor) or Src, 23, 33 we hypothesized that BMPER may initiate signaling cascades directly through LRP1. Treatment with BMPER at increased dosages promoted ERK activation. However, ERK activation induced by BMPER was not inhibited by BMP4-neutralizing antibody ( Figure 4B ; Figure IVB in the online-only Data Supplement), suggesting that BMPER may induce ERK activation in a BMP4-independent manner. However, LRP1 knockdown dramatically decreased ERK activation on BMPER treatment in MLECs that have been transiently transfected with LRP1 siRNA or mouse endothelial cells being stably transfected with LRP1 shRNA (short hairpin RNA; EC 50 is 51.20 nmol/L; Figure 4C ; Figure   IVC in the online-only Data Supplement), suggesting that LRP1 is required for BMPER-induced ERK activation. Given that ERK pathway is required for BMPER-induced NFAT activation, we then tested whether LRP1 is required for NFAT activation. LRP1 knockdown significantly inhibited NFAT reporter activity in response to BMPER in MLECs ( Figure 4D ). More importantly, interferon γ mRNA levels were increased by BMPER, lipopolysaccharide, or their combined treatments. These increases were inhibited by LRP1 knockdown in MLECs ( Figure 4E ). Taken for all, these results suggest that ERK activation mediated by LRP1 and calcium-dependent calcineurin pathways are required for NFAT activation on BMPER treatment. Many NFAT regulatory elements can also be regulated by NFκB. For example, CD28 were transfected with constructs of NFAT-responsive luciferase, renilla, and inhibitory Smad-Smad6. After 24 h, cells were pre-treated with cyclosporine A (CsA), U0126 for half an hour, and then treated with BMPER or control. Luciferase activity was measured after another day's incubation. B, BMPER-induced ERK activation is not inhibited by BMP4-neutralizing antibody in MLECs. Mouse cardiac-derived endothelial cells were treated with BMPER at indicated doses for 30 min. BMP4-neutralizing antibody (NAb; 40 ng/mL) was used to pre-treat cells to block BMP4 activity ( Figure IVB in the online-only Data Supplement). C, BMPER increases LRP1-dependent ERK activation. MLECs transiently transfected with LRP1 small interfering RNA (siRNA) were treated with BMPER at 10 nmol/L for 30 min and then harvested for Western blotting. ERK activity was calculated by measuring the intensity of phospho-ERK and total ERK blots. D, LRP1 is required for NFAT activation induced by BMPER. MLECs were transfected with LRP1 or control siRNA, and NFAT-responsive luciferase and renilla constructs. After 24 h, cells were treated with BMPER or control. Luciferase activity was measured after another day's incubation. E, LRP1 is required for interferon (IFN) γ induction on lipopolysaccharide (LPS), BMPER, or their combined treatments. MLECs were transfected with LRP1 or control siRNA. After 24 h, cells were treated with LPS at 10 μg/mL, BMPER at 10 nmol/L, their cotreatment, or control, and then incubated for another 8 h. Cells were harvested for real-time polymerase chain reaction with IFNγ-specific probe and primers. *P<0.05, compared with control cells without BMPER or other indicated treatments; #P<0.05, compared as indicated (for A, C, and D) or to control siRNA-transfected cells on same treatments (for E); n=3 to 4. Analysis was 2-way ANOVA followed by Fisher least significant difference multiple comparison test. NA indicates not significant. , and 4′,6-diamidino-2-phenylindole (blue) for nucleus, and representative pictures were shown in (D). LRP1 (C-terminal) antibody recognizes both LRP1β and its processed fragments at 25 and 12 kDa intracellular domain. The relative intensity of LRP1β and its processed fragments, and NF45 in nuclear and cytoplasmic fractions, was quantified, and the ratios of nuclear to cytoplasmic signals were presented in (D). *P<0.05, compared with control cells; n=8 to 12. In addition, MLECs were treated with BMPER, and fractionation assays were performed. Band intensity of LRP1β, its intracellular domain at 12 kDa (LRP1-ICD), and NF45 was calculated and normalized to the sample without BMPER treatment. The graph in (E) shows a decrease in nuclear NF45, LRP1β, and LRP-ICD protein levels but an increase in cytosolic NF45, LRP1β, and LRP1-ICD. The protein level of the LRP1β processed form at 25 kDa was not changed in the cytosol in response to BMPER treatment. *P<0.05, compared with cells without BMPER treatment; n=3. F, NF45 knockdown promotes NFAT activity. MLECs were transfected with a mixture of NFAT-responsive firefly luciferase and renilla constructs, and NF45 or control small interfering RNA (siRNA). One day later, cells were treated with BMPER at 10 nmol/L, and the luciferase activity was measured after another day's incubation. *P<0.05, compared with cells without BMPER treatment; #P<0.05; n=3. Analysis was Student t test (for D), 1-way ANOVA (for E), and 2-way ANOVA followed by Fisher least significant difference multiple comparison test (for F). R.L.U. indicates relative light units.
response element of the IL-2 promoter contains a dimeric NFAT/ NFκB site, which may bind both NFAT and NFκB and function co-operatively with AP-1 (activator protein-1) protein that is associated with the adjacent AP-1 site. 34 ,35 Therefore, we tested whether BMPER can also activate NFκB transcriptional activity. In response to BMPER treatment, NFκB transcriptional activity was increased, determined by NFκB reporter assays ( Figure IVD in the online-only Data Supplement). However, LRP1 knockdown by its specific siRNA decreased BMPER-induced NFκB activity. It suggests that BMPER/LRP1 axis can also activate NFκB transcriptional activity.
NF45 Is Associated With LRP1β and Involved in NFAT Activation
In addition, LRP1β can be further processed 36 and translocated to nucleus, where it interacts with nuclear proteins such as poly(ADP-ribose) polymerase-1 24 and PPARγ 25 to regulate cell cycle progression and gene transcription. Interestingly, we observed that LRP1β and its processed intracellular domain (≈12 kDa) were localized in the nucleus at basal condition, and their levels were decreased after the treatment of DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a γ-secretase inhibitor (an inhibitor of presenillin-dependent γ-secretase activity), to generate the intracellular domain of LRP1 (≈12 kDa) from the ≈25 kDa processed form 24, 36 ( Figure VA and VB in the online-only Data Supplement). It is unclear why DAPT decreased LRP1β level in the nucleus. However, on DAPT treatment, the level of the ≈25 kDa fragment of LRP1 was increased in the cytosolic fraction, suggesting that LRP1β processing takes place at basal condition in a γ-secretase-dependent manner. Because we have demonstrated that LRP1 is required for BMPER-induced ERK activation ( Figure 4C ), we wanted to determine whether the nuclear LRP1β might play a role in BMPER-induced NFAT activation. To address this question, we started a search for LRP1β-interacting proteins as shown in our previous publication. 24 First, we performed liquid chromatography-associated mass spectrometry analysis to identify LRP1β-associated proteins in HEK 293 (human embryonic kidney 293) cells ( Figure 5A ). NF45/interleukin-binding factor 2 was among proteins that coimmunoprecipitated with Flag-LRP1β ( Figure 5A ). NF45 is a nucleic acid-binding protein that regulates cellular gene expressions involved in DNA metabolism, transcription, translation, RNA export, and microRNA biogenesis. [37] [38] [39] [40] [41] In addition, NF45 is considered as a transcriptional activator of IL-2 gene. 42 Previous reports show that NF45 and NFAT bind to the same promoter region of IL-2 promoter. However, they have different consensus binding sequences (TGTTTAC for NF45 and TGGAAAAT for NFAT). 43 NF45, unlike NFAT, is associated with the IL-2 ARRE-2 site even at basal condition. 43 To date, it remains unknown whether this interchangeable binding of NF45 and NFAT transcriptional complex is important for IL-2 transcriptional activation. To study the role of NF45 in BMPER-induced gene expression, we first confirmed the interaction between overexpressed Flag-LRP1β and NF45 in HEK 293 cells ( Figure 5B) . Moreover, their endogenous association was detected in MLECs and blocked by the inhibitors of PKA-PKI (protein kinase A inhibitor), Src (PP2), or their combined treatments ( Figure 5C ; Figure VC in the online-only Data Supplement), suggesting that the interaction of LRP1β with NF45 requires LRP1β phosphorylation by PKA and Src. Furthermore, both immunofluorescence imaging and subcellular fractionation analysis demonstrated that LRP1β and its processed intracellular domain and NF45 were colocalized mainly in the nucleus of MLECs at basal condition ( Figure 5D and 5E) . Surprisingly, cytosolic levels of NF45, LRP1β, and its intracellular domain, but not the processed form of LRP1β at 25 kDa, were increased in response to BMPER treatment ( Figure 5E ), suggesting that BMPER induces the cytosol translocation of NF45, LRP1β, and its intracellular domain, but not the LRP1 processing. To further test whether NF45 translocation takes place in lipopolysaccharide-induced inflammatory setting, we performed immunofluorescent studies in MLECs and lung sections. In lipopolysaccharide-treated MLECs, NF45-positive signals in the cytosol fraction were significantly increased ( Figure  VD and VE in the online-only Data Supplement). However, the increased signals were blocked in BMPER siRNA-transfected MLECs. In addition, 70.6% of NF45 signals were localized in cytosol of pulmonary vascular cells in BMPER +/+ mice on lipopolysaccharide injection ( Figure VF and VG in the onlineonly Data Supplement). However, the cytosol-localized NF45 signals were decreased to 55.1% in BMPER +/− mice. All these results indicate that NF45 was translocated from the nucleus to cytoplasm in response to lipopolysaccharide, and its translocation was inhibited by BMPER deficiency, which supports the hypothesis that NF45 nuclear export is regulated by lipopolysaccharide through a BMPER-dependent pathway.
In the meantime, we observed the translocation of NFATc1 from cytoplasm to nucleus ( Figure 3C and 3D) . Therefore, we hypothesize that NF45 may negatively regulate NFAT activity by competing to bind the promoter region of NFAT target genes. As expected, knockdown of NF45 by its specific siRNA significantly increased NFATc1 chromatin occupancy and its promoter activity at basal condition and in response to BMPER treatment ( Figure 5F ; Figure VIA in the online-only Data Supplement). In addition, when LRP1 was knocked down in MLECs, both BMPER-induced NF45 nuclear export and NFATc1 cytoplasmic-nuclear shuttling were inhibited (Figure VIB-VIE in the online-only Data Supplement). When LRP1 α chain was blocked by its specific antibody 8G1, BMPER-induced NF45 nuclear export was also blocked ( Figure VIF and VIG in the onlineonly Data Supplement), suggesting that 2 signaling pathways, including the membrane LRP1-associated LRP1β signaling and nuclear LRP1β-NF45 signaling, are interdependent. However, exact mechanisms by which these 2 pathways are integrated remain unclear and will become one of our future research directions. Nevertheless, we conclude that NF45 acts as a repressor for NFAT activation, and its nuclear export with LRP1β may contribute to BMPER-induced activation of NFATc1.
Taken all together, our results indicate that BMPER acts as a proinflammatory stimulus during acute lung injury. Its action requires co-ordinative actions of multiple signaling cascades, including the calcium-dependent calcineurin and LRP1-dependent ERK activation, the cytosolic translocation of NF45 and nuclear translocation of NFATc1, which eventually lead to the activation of NFATc1 and induction of its downstream inflammatory target genes ( Figure 6 ). Our study provides BMPER signaling as a potential therapeutic target in preventing sepsis-induced pulmonary inflammation and injury.
Discussion
The roles of BMPER in inflammation have been examined in several mouse models of inflammation, including thioglycollate-induced peritonitis and high-fat diet-induced atherosclerosis. 14, 15 The studies suggest that BMPER plays an anti-inflammatory role through modulating BMP activity and thereby blocking TNF-α or oscillatory shear-mediated induction of adhesion molecules, such as ICAM-1 (intercellular adhesion molecule 1) and VCAM1 (vascular cell adhesion molecule 1). In this study, we have demonstrated for the first time a proinflammatory role of BMPER in lipopolysaccharide-induced acute lung injury. BMPER +/− mice exhibit alleviated responses on lipopolysaccharide challenge. Our biochemical studies suggest that BMPER regulates inflammatory responses through NFAT pathway, which plays important roles in endothelial inflammation. In addition, we provide evidence suggesting that BMPER may initiate its own signaling pathways via LRP1, which expands our understanding in the roles of BMPER in vascular homeostasis.
How BMPER may play a proinflammatory role in lipopolysaccharide-induced acute lung injury? Our gene expression profiling analysis provided us a clue by suggesting that BMPER may regulate NFAT transcriptional activity. We then confirmed that BMPER is not only required but also sufficient for NFAT activation, which plays an essential role in proinflammatory cytokines production in endothelial cells during lipopolysaccharide-induced endotoxemia. 7 This BMPER-induced signaling event involves co-ordinative actions of multiple pathways. As we propose in the working model ( Figure 6 ), BMPER activates ERK pathway in a LRP1-dependent manner, which is required for NFAT activation. Although it remains to be further determined how calcium/calcineurin signaling is activated by BMPER, the studies with calcineurin inhibitor cyclosporine suggest that calcium/calcineurin is also required for BMPER-induced NFAT activation. In addition, we discovered that LRP1β is associated with NF45 in the nucleus at basal condition. On BMPER stimulation, they are translocated to cytoplasm in a timely fashion when NFATc1 is translocated into nucleus. Given that NFATc1 and NF45 are associated with the same promoter regions of their genes, these observations indicate that NF45 may suppress NFAT transcriptional activity at basal condition. On the stimulation, the replacement of NF45 by NFAT transcriptional complex could be allowed in a fast fashion, which may explain the quick transcriptional events for proinflammatory cytokines. These timely reactions of endothelial cells, acting as the first line of defense, are essential for fighting against septic shock and the resolution of the acute inflammation. We and others have identified both pro-and anti-BMP activities of BMPER, 11, 12, [44] [45] [46] [47] [48] [49] [50] [51] resulting in some controversy as to whether BMPER is a BMP agonist or antagonist. To reconcile this issue, we have extensively analyzed the biochemical events resulting from BMPER's interaction with BMP4 and identified a concentration-dependent switch of BMPER from pro-to anti-BMP signaling, which is modulated by the relative concentration of BMPER to BMP4. 16 Specifically, when BMPER is at molar concentrations lower than BMP4 (substoichiometric), BMP4 activity is enhanced, leading to increased phosphorylation of Smad1/5/8 in mouse endothelial cell. However, when BMPER is at molar concentrations higher than BMP4 (suprastoichiometric), BMP4-mediated Smad1/5/8 phosphorylation is attenuated. Both the activation and inhibition of BMP4 signaling by BMPER require endocytosis of BMPER/BMP4 complex through a clathrin-dependent endocytosis pathway, suggesting that endocytosis of BMPER/BMP4 complex is involved in BMPER-mediated BMP4 signaling. This provides molecular mechanisms to support a role of BMPER in fine tuning BMP signaling at the single cell level. However, it may not necessarily explain all the pro-and anti-BMP phenotypes in different animal models. In this study, we provide strong evidence suggesting that BMPER, besides acting as an extracellular modulator of BMP, may also initiate its own signaling through LRP1 in endothelial cells. Even though this adds another layer of complexity to BMPER's functional roles, it provides feasible explanations for BMPER's different, sometimes even controversial, loss-of-function phenotypes in different animal models.
Lipopolysaccharide-induced NFAT pathway plays a pivotal role in vascular endothelial activation. In endothelial cells, TLR4 and likely CD14 too are main receptors of lipopolysaccharide. However, it is unclear whether TLR4 and CD14 are required for NFAT activation. In this study, we have discovered that BMPER is required and sufficient for NFAT activation. It will be interesting to determine how BMPER regulates lipopolysaccharide-induced NFAT activation. LRP1 has been reported to transactivate Trk receptors through an Src-family kinase-dependent pathway. 52 It is likely that crosstalks may also exist between LRP1 and TLR4, CD14 and their downstream mediators, which coordinately regulate NFAT activation. The detailed protein-protein interactions responsible for this crosstalk will become one of our further research directions.
It is worth to note that the decrease of BMPER expression in the BMPER +/− mouse is not limited in endothelial cells. Because BMPER is a secreted protein, it can act on many different cell types. In addition, inflammation is a multicellular process that involves not only endothelial cells but also other cells, such as circulating leukocytes and lung epithelial cells. Even though our investigation has only been focused on lung endothelial cells, the role of BMPER in sepsis or other lung inflammatory pathogenesis may be more complicated than what we observed within this endotoxemia model. Previous studies show that the decreased BMPER expression after bleomycin-induced lung injury impairs epithelial barrier function and epithelial morphology. 53 It is likely that BMPER haploinsufficiency also regulates functions of epithelial cells, neutrophils, or other cell types during lipopolysaccharide-induced acute lung injury, which remains to be further investigated. Nevertheless, given that BMPER is accessible as a secreted protein, our findings shed light that BMPER may become a great therapeutic target during endotoxemia, septic shock, and other pulmonary inflammatory conditions.
